The health care industry is a critical component of
economies worldwide. As economic meltdown begins drug/supplement companies are
trending towards shelving early-stage projects and working on late phase
development. In a shaky economy, demand from clients is slack. As these
companies move to rationalize their pipelines, CRO's are competing for fewer
projects and RnD dollars while trying to achieve the same scale as in years
past. A slump in early phase development is not bad news. Contract research
organizations begin to engage in preferred partnership and strategic alliances
to combat the Big R – ‘Recession’
No comments:
Post a Comment